<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-6063-25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1987
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HOLOXAN 1GM I.V. VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IFOSFAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        141.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAXTER ONCOLOGY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAXTER ONCOLOGY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAXTER ONCOLOGY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Holoxan<strong> </strong>is a cytotoxic drug or anti-cancer drug. It works by killing cancer cells, this is sometimes called &lsquo;chemotherapy&rsquo;.</p><p>It is used to treat lots of different cancers. Holoxan<strong> </strong>is often used together with other anti-cancer drugs or radiotherapy.</p><p>&nbsp;</p><p><strong>Important things to know about Holoxan</strong></p><p>Your doctor has prescribed Holoxan because you have cancer that can be treated.</p><p>Holoxan is a medicine that kills cancer cells but, as a result, also attacks normal cells. It can therefore have a number of side effects. Your doctor will not give you Holoxan unless he or she thinks that your cancer is more of a risk to you than any possible side effects. Your doctor will check you regularly and treat any side effects where possible.</p><p>Holoxan:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will reduce your blood cell count, which may make you feel tired and be more likely to get infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can affect your kidneys and bladder. You may be given another medicine called Mesna to help prevent any damage. If you notice blood in your urine, tell your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can cause mental problems, such as confusion, feeling unusually sleepy and more seriously, fits and loss of consciousness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; like most anti-cancer or chemotherapy medicines, you may lose your hair (anything from thinning to total loss), although it should start to grow back once your treatment has finished.&nbsp; It may also make you feel sick or be sick.&nbsp; Your doctor can give you advice or medicines to help.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Men or women should not have a child during treatment with Holoxan or for at least 6 months after treatment. You should use an effective contraceptive. Ask your doctor for advice.</p><p><strong>Now read the rest of this leaflet. </strong>It includes other important information on the use of Holoxan that might be especially important for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You will not be given Holoxan if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had an allergic reaction to Ifosfamide. An allergic reaction can include shortness of breath, wheezing, rash, itching or swelling of the face and lips</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a condition which decreases your ability to urinate (Urinary outflow obstruction).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your bone marrow is not working properly (especially if you have previously had chemotherapy or radiotherapy). You will have blood tests to check how well your bone marrow is working</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a urinary tract infection, which can be recognised as pain when passing urine (cystitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your liver and kidneys are not working properly.&nbsp; You will have blood tests to check this.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you currently have any infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had kidney or bladder problems as a result of previous chemotherapy or radiotherapy.</p><p>&nbsp;</p><p><strong>Tell your doctor if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are already having, or have recently had, radiotherapy or chemotherapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;you have liver or kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have been treated with cisplatin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have poor general health or are frail</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are elderly.</p><p>&nbsp;</p><p>If any of the above apply to you your doctor may need to do extra tests on your blood or urine and may decide to change your treatment.</p><p><strong>Take special care with Holoxan:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can have effects on your blood and immune system.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood cells are made in your bone marrow.&nbsp; Three different types of blood cell are made:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red blood cells, which carry oxygen around your body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; white blood cells, which fight infection, and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; platelets, which help your blood to clot.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After taking Holoxan, your blood count of the three types of cells will drop.&nbsp; This is an unavoidable side effect of Holoxan. Your blood count will reach its lowest level about 5 to 10 days after you start taking Holoxan and will stay low until a few days after you finish the course.&nbsp; Most people recover to a normal blood count within 21 to 28 days. If you have had a lot of chemotherapy in the past, it may take a little longer to return to normal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be more likely to get infections when your blood count drops.&nbsp; Try to avoid close contact with people who have coughs, colds and other infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will check that the number of red blood cells, white blood cells and platelets is high enough before and during your treatment with Holoxan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can affect wound healing. Keep any cuts clean and dry, and check they are healing normally.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important to keep your gums healthy, as mouth ulcers and infections can occur. Ask your doctor about this if you are unsure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can damage the lining of your bladder, causing bleeding into your urine. Your doctor knows this can happen and, if necessary, he or she will give you a medicine called Mesna which will protect your bladder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mesna can either be given to you as a short injection, or mixed into the drip solution with your Holoxan, or as tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; More information on Mesna can be found in the Patient Information Leaflet for Mesna Injection and Mesna tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Most people having Holoxan with Mesna do not develop any problems with their bladder, but your doctor may want to test your urine for the presence of blood using a &lsquo;dipstick&rsquo; or microscope.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you notice that you have blood in the urine, you must tell your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can damage your kidneys so that they do not work properly.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is more likely to happen if you only have one kidney or if your kidneys are already damaged.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is often temporary and they return to normal once Holoxan therapy is stopped.&nbsp; Occasionally the damage is permanent and more severe.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will check your test results for signs of kidney damage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer medicines and radiation therapy can increase the risk of you developing other cancers; this can be a number of years after your treatment has stopped.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can cause damage to your heart or affect the rhythm of it beating.&nbsp; This increases with higher doses of Holoxan, if you are being treated with radiation or other chemotherapy medicines or if you are elderly. Your doctor will monitor your heart closely during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can cause inflammation or scarring in your lungs.&nbsp; This can occur more than six months after your treatment. If you start having difficulty breathing tell your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can have life threatening effects on your liver.&nbsp; If you have sudden weight gain, liver pain and jaundice tell your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Hair thinning or baldness can occur.&nbsp; Your hair should grow back normally though it may be different in texture or colour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can make you feel sick or be sick.&nbsp; This can last for about 24 hours after taking Holoxan. You may need to be given medicines to stop feeling or being sick.&nbsp; Ask your doctor about this.</p><p><strong>&nbsp;</strong></p><p><strong>Using other medicines and treatments</strong></p><p>Tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines you have bought yourself.</p><p>In particular, tell them about the following medicines or treatments as they may not work well with Holoxan:</p><p>&nbsp;</p><p><strong>The following medicines can increase the toxicity of Holoxan:</strong></p><p><strong>medicines that can increase the toxic effects on your blood cells and immunity: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACE inhibitors (used to treat high blood pressure).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carboplatin (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisplatin (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Natalizumab (used to treat multiple sclerosis)</p><p>&nbsp;</p><p><strong>medicines that can increase the toxic effects on your heart: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anthracyclines such as bleomycin, doxorubicin, epirubicin, mitomycin (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; radiation in the area of your heart</p><p><strong>medicines that can increase the toxic effects on your lungs: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amiodarone (used to treat irregular heart beat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; G-CSF, GM-CSF hormones (used to increase white blood cell numbers after chemotherapy)</p><p><strong>medicines that can increase the toxic effects on your kidneys : </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acyclovir (used to treat viruses)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aminoglycosides (used to treat bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amphotericin B (used to treat fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carboplatin (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisplatin (used to treat cancer)</p><p><strong>medicines that can increase the toxic effects on your bladder: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Busulfan (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irradiation of the bladder</p><p><strong>medicines that can cause additive&nbsp; effects on you central nervous system when combined with Holoxan</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antiemetics ( used to control vomiting and nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antihistamines ( used to treat allergic reactions)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Narcotics</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sedatives</p><p><strong>the following medicines can increase the toxicity of Holoxan: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine ,Phenytoin, Phenobarbital (used to treat epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids (used to treat inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampin (used to treat bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s (a herbal remedy for mild depression)</p><p>&nbsp;</p><p><strong>the following medicines can reduce how effective Holoxan is: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole ,Fluconazole ,Itraconazole (used to treat bacterial or protozoal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sorafenib ( used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aprepitant (used to prevent being sick)</p><p><strong>other medicines that can affect or be affected by Holoxan include:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Docetaxel( used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coumarins such as warfarin (used to thin the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaccines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tamoxifen: (used to treat breast cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisplatin: (used to treat cancer).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irinotecan : (used to treat cancer)</p><p><strong>Using Holoxan with food and drink</strong></p><p>Drinking alcohol can increase the nausea and vomiting caused by Holoxan.</p><p><strong>Pregnancy, breast-feeding and contraception</strong></p><p>Do not become pregnant while taking Holoxan. This is because it can cause miscarriage or damage your unborn baby. Tell your doctor if you are pregnant, think you might be pregnant or are trying to become pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Men or women should not try to have a child during or for at least 6 to 12 months after treatment. You should use an effective contraceptive. Ask your doctor for advice.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan can affect your ability to have children in the future. Talk to your doctor about freezing sperm samples or eggs before your treatment starts.</p><p>Do not breast-feed while being treated with Holoxan. Ask your doctor for advice.</p><p><strong>Driving or operating machines</strong></p><p>Some of the side effects of treatment with Holoxan might affect your ability to drive and use machines safely. Your doctor will decide if it is safe for you to do so.</p><p><strong>What to do if you see a different doctor, or have to go to hospital</strong></p><p>If you see any other doctor or have to go to hospital for any reason, tell them what medicines you are taking. Do not take any other medicines unless your doctor knows you are taking Holoxan.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Holoxan will be given to you by a doctor or nurse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan will normally be added to a large bag of fluid and will be slowly injected (infused) directly in to your vein.&nbsp; The vein can be in your arm, the back of your hand or a large vein under your collar bone.&nbsp; Depending on your dose, the Injection usually takes several hours but may be given over several days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holoxan is often given with other anti-cancer drugs or radiotherapy.</p><p><strong>The usual dose</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide how much of the medicine you need and when you should take it.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The amount of Holoxan you will need to take depends on:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; the type of illness you have</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; how big you are (a combination of your height and weight)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; your general health</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; whether you are being given other anti-cancer drugs or having radiotherapy.</p><p>&nbsp;</p><p>Holoxan is usually given as a series of courses of treatment.&nbsp; After a course there is a break (a period when no injections are given) before the next course.</p><p>&nbsp;</p><p><strong>If you are given too much Holoxan</strong></p><p>It is unlikely that you will be given more Holoxan than you should, because it will be given to you by a trained and qualified person.&nbsp; They would stop the injection straightaway if too much was given.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Holoxan can cause side effects, although not everybody gets them. The following side effects may happen with this medicine.</p><p><strong>Tell your doctor straight away, if you notice any of the following serious side effects:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; getting bruises without knocking yourself, being slow to stop bleeding or bleeding from your nose or gums. This may be a sign that the platelet levels in your blood are getting too low</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a lowering of your white blood cell count, your doctor will check this during your treatment. It will not cause any signs, but you will be more likely to get infections. If you think you have an infection (a high temperature, feeling cold and shivery, or hot and sweaty, or any signs of infection such as a cough, or stinging on passing water) you may need antibiotics to fight infections because your blood count is lower than usual</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very pale, lethargic and tired. This may be a sign of low red blood cells (anaemia). Usually, no treatment is required, your body will eventually replace the red blood cells. If you are very anaemic, you may need a blood transfusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in your urine, pain, or less being passed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mental state changes.&nbsp; In some people Holoxan can affect the brain.&nbsp; Sometimes people on Holoxan do not realise that they have been affected but friends and relatives may notice a change in them. If any of the following side effects are seen your doctor will stop your treatment with Holoxan.&nbsp;</p><p>- mania</p><p>- paranoia</p><p>- delusion</p><p>- delirium</p><p>- amnesia</p><p>- motionless and unresponsive to stimuli (catatonia)</p><p>- panic attack</p><p>- inability to speak (mutism)</p><p>- repeating words (echolalia)</p><p>- being fixed on a task (perseveration)</p><p>&nbsp;</p><p><strong>Other possible side effects may be:</strong></p><p>&nbsp;</p><p>Immune system and Infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions, signs of this would be shortness of breath, wheezing, rash, itching or swelling of the face and lips (hypersensitivity). Severe allergic reactions could lead to difficulty in breathing or shock, with a possible fatal outcome (anaphylactic shock, anaphylactic/anaphylactoid reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in the effectiveness of your immune system (immunosuppression).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased risk and severity of bacterial, fungal, viral, protozoal or parasitic infections due to the effect of Holoxan on your immune system</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactivation of infections you have had before (latent infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe infection spreading through the blood which may lead to a dangerous drop in blood pressure with a possible fatal outcome (sepsis, shock).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the skin around the face, inside of the mouth and throat (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a skin rash of red itchy swellings (urticaria)</p><p>&nbsp;</p><p>Cancers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; secondary tumours in various parts of the body, often in the area of the bladder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; progression of underlying cancers</p><p>&nbsp;</p><p>Blood and Lymphatic System</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the activity of your bone marrow (myelosuppression).</p><p>This can cause a decrease in the number of cells in your blood:</p><p>&ndash; white cells - which fight infection (leucopenia, agranulocytosis). This may be associated with fever (febrile bone marrow aplasia)</p><p>&ndash; platelets - which help your blood clot (thrombocytopenia)</p><p>&ndash; red cells - which carry oxygen around the body (anaemia, neonatal anaemia, haemolytic anaemia)</p><p>This may be associated with a decrease in their ability to carry oxygen (methaemoglobinaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; formation of small blood clots in your blood vessels disrupting the normal blood flow around your body (disseminated intravascular coagulation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemolytic uremic syndrome &ndash; a condition causing abnormal break down of the red blood cells, decreased numbers of platelets in the blood and kidney failure.</p><p>&nbsp;</p><p>Endocrine System</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the release of antidiuretic hormone from the pituitary gland (SIADH). This affects the kidneys causing the low levels of sodium in your blood (hypernatraemia) and water retention.</p><p>&nbsp;</p><p>Metabolism and Nutrition</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss or decrease of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to your metabolism caused by the breakdown of the dying cancer cells (Tumour lysis syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of acidity of body fluids (metabolic acidosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood levels of potassium which can cause abnormal heart rhythms , constipation, fatigue, muscle weakness or spasms, depression,&nbsp;psychosis,&nbsp;delirium, confusion, or hallucinations (hypokalaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood levels of calcium which can cause muscle cramps and twitching, irregular heartbeat, overactive reflexes, and burning or tingling sensations in the hands and feet (hypocalcaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood levels of phosphate which can cause bone pain, confusion and muscle weakness (hypophosphataemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar levels which can cause thirst, tiredness and irritability (hyperglycaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive thirst that is also accompanied by excessive fluid intake (polydipsia).</p><p>&nbsp;</p><p>Digestive system</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick and being (nausea, vomiting).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lining of your mouth, including ulcers (stomatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of your intestines or bowel&nbsp; (enterocolitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe tummy and back pain which may be from inflammation of the pancreas (pancreatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease bowel activity which may lead to bowel obstruction (ileus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in your stomach or intestines (gastrointestinal haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulceration of the lining of the digestive system (mucosal ulceration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased saliva production</p><p>&nbsp;</p><p>Nervous System</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a disorder of the nerves which can cause weakness, tingling or numbness (peripheral neuropathy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; having difficulties in&nbsp; controlling or coordinating the muscles you use when you speak, or weakness of those muscles (Dysarthria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a syndrome called Status epilepticus (convulsive and nonconvulsive) defined as one continuous, unremitting seizure lasting longer than 5 minutes,&nbsp;or recurrent seizures without regaining consciousness between seizures for greater than 5 minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on the brain (encephalopathy), signs of this can be problems in thinking or concentrating, reduced alertness, changes in personality, tiredness, fits, muscle twitching, and shaking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; movement disorders and gait disturbances (movement disorder, extrapyramidal disorder, gait disorder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on the spinal cord (myelopathy), which can cause numbness, weakness and tingling in the hands, loss of motor skills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain from your nerves, which can also feel like an aching or burning sensation (neuralgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flapping tremor of the hand (asterixis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness, often in the hands or feet (paresthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of sense of touch or sensation (hypoesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to control bowel movements (faecal incontinence).</p><p>&nbsp;</p><p>Eyes and Ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurring, reduction or loss of sight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eye (conjunctivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritation of the eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deafness or hearing impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness or feeling of spinning (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears (tinnitus)</p><p>&nbsp;</p><p>Heart and Circulation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the heart muscle (cardiotoxicity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in your heart rhythm (arrhythmia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart beat (atrial fibrillation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; early heartbeat (premature atrial contractions)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower heart beat (bradycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack (myocardial infarction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in your hearts ability to pump enough blood around your body which may be life threatening (cardiac failure or cardiac arrest)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in to the muscles of the heart (myocardial haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain from reduced blood supply to the heart (angina pectoris)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disease of the heart muscle (cardiomyopathy, congestive cardiomyopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal ECG heart tracing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot in the lungs which causes chest pain and breathlessness (pulmonary embolism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot, usually in a leg, which causes pain swelling or redness (deep vein thrombosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leaking of fluid from the circulation into surrounding tissues (capillary leak syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels (vasculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low or high blood pressure (hypotension, hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddening of the skin (flushing)</p><p>&nbsp;</p><p>Lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-threatening decrease of your lungs ability to transfer oxygen in to your blood (respiratory failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; conditions causing inflammation of the lungs which can cause breathlessness, cough and raised temperature or scarring of the lungs (pneumonitis, acute respiratory distress syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; scarring of the lungs which causes shortness of breath (interstitial lung disease, pulmonary fibrosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluid in or around the lungs (pulmonary oedema, pleural effusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure in the lungs which can cause shortness of breath, fatigue, cough, angina, fainting, peripheral oedema (pulmonary hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath (dyspnea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease levels of oxygen in your body (hypoxia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&nbsp;</p><p>Liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a build up of toxins in the body due to liver failure (hepatotoxicity).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blockage of the small veins in your liver (veno-occlusive liver disease) which can cause weight gain, increased liver size, pain and jaundice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction of blood supply or blockage of the portal vein of the liver (portal vein thrombosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver which can cause jaundice, weight loss and malaise (cytolytic hepatitis)</p><p>&nbsp;</p><p>Skin and Subcutaneous Tissue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss ( alopecia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of this skin which may cause rash, blisters, itching, sores, oozing and scarring (dermatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin eruption or reaction consisting of small, round, raised bumps that have clear borders (popular rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life threatening conditions which cause rash, ulcers, sore throat, fever, conjunctivitis, separation of skin layers (toxic epidermal necrolysis, Stevens-Johnson syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, numbness, red lumps and peeling of skin on the hands and feet (Palmar-plantar erythrodysesthesia syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness and blistering of the skin appearing months or years after treatment (Radiation recall dermatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy, red rash which can develop in to sores (erythema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in colour of your fingernails and skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; separation of the nail bed which can cause nails to fall off</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating (hyperhidrosis)</p><p>&nbsp;</p><p>Musculoskeletal and Connective Tissue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal muscle breakdown which can lead to kidney problems (rhabdomyolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; softening of the bones that could cause severe bone pain, pain caused by slight crack in the bone back pain, partial or complete fractures and muscle weaknesses (osteomalacia, rickets)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; growth retardation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain (myalgia) or joint pain (arthralgia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle twitching</p><p>&nbsp;</p><p>Renal and Urinary</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the bladder lining which causes pain, bleeding, blood in the urine, reduced urine flow (haemorrhagic cystitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in the urine (haematuria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life threatening decrease in the abilities of your kidney to adequately remove toxins and waste products from the blood (renal dysfunction, renal failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney malfunction causing increased of total urine amino acids into urine (aminoaciduria). Your doctor will do urine tests to test for these.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney malfunction causing urine to appear cloudy or murky colour (phosphaturia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney malfunction leads to excessive urine production and excessive thirst, resulting in deficits of water, calcium, potassium, magnesium, and other substances in the body (fanconi syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidneys (tubulointerstitial nephritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to the structure of your kidneys which prevent them from working correctly (renal structural damage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glucose in the urine (nephrogenic diabetes insipidus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; condition usually defined as excessive or abnormally large production or passage of urine (polyuria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repeated inability to control urination (enuresis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of residual urine</p><p>&nbsp;</p><p>&nbsp;</p><p>Pregnancy and Fertility</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infertility. Sperm production in men and egg production in women may be reduced or stop. In some cases this can be permanent</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of&nbsp;ovarian&nbsp;function before age 40 (ovarian failure , premature menopause)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; absence of menstrual periods (amenorrhea) or absence of ovulation (ovulation disorder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; absence of measurable level of sperm in male semen (azoospermia) or less number of sperm in the ejaculate of the male&nbsp;(oligospermia)</p><p>&nbsp;</p><p>Congenital, Familial and Genetic Disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in growth, deformity or death of a foetus while in the womb</p><p>&nbsp;</p><p>General Disorders and Administrative Site Conditions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of a vein, usually in the legs (phlebitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of general discomfort or uneasiness (malaise)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life threatening failure of multiple organs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general physical deterioration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; appearance of skin changes and irritation at the&nbsp;site of injection or infusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet.&nbsp; You can also report side effects directly (see details below).&nbsp; By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><ul><li><strong>Saudi Arabia:</strong></li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Because Holoxan is usually given in hospital is will be stored safely and correctly by the hospital staff. If you do need the storage conditions they are given below.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Holoxan after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 25&ordm;C. Store in the original container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What</strong><strong> Holoxan contains</strong></p><p>The active substance is Holoxan and each vial contains 500 mg or 1&nbsp;g or 2&nbsp;g.</p><p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Holoxan looks like and contents of the pack
Holoxan is a dry white powder supplied in clear glass vials.  Each carton contains 1 vial.
The contents of each vial has to be mixed with sterile water (called ‘water for injections’) before use.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Baxter Oncology GmbH</p><p>Kantstra&szlig;e 2</p><p>33790 Halle/Westphalia</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            NA
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Holoxan Injection 1000 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 1000 mg of Ifosfamide.

When reconstituted as directed, each milliliter of concentrate contains 80 mg Ifosfamide

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion. White powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Holoxan &nbsp;is a cytotoxic drug for the treatment of malignant disease. As a single agent it has successfully produced objective remissions in a wide range of malignant conditions. Holoxan &nbsp;is also frequently used in combination with other cytotoxic drugs, radiotherapy and surgery.</p><p>Children and adolescents - see section 5.1-Paediatric population</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Holoxan &nbsp;should only be administered when there are facilities for regular monitoring of clinical, biochemical and haematological parameters before, during and after administration and under the direction of a specialist oncology service by physicians experienced with this drug.</p><p>&nbsp;</p><p>Dosage must be individualised. Doses and duration of treatment and/or treatment intervals depend on the therapeutic indication, the scheme of a combination therapy, the patient&rsquo;s general state of health and organ function, and the results of laboratory monitoring.</p><p>&nbsp;</p><p>In combination with other agents of similar toxicity, a dose reduction or extension of the therapy-free intervals may be necessary.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>A guide to the dosage regimens used for most indications is given below:</p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 - 12 g/m&sup2; equally fractionated as single daily doses over 3 - 5 days every 2 - 4 weeks.</p><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 - 6 g/m&sup2; (maximum 10 g) given as a 24 hour infusion every 3 &ndash; 4 weeks.</p><p>&nbsp;</p><p>The frequency of dosage is determined by the degree of myelosuppression and the time taken to recover adequate bone marrow function. &nbsp;The usual number of courses given is 4, but up to 7 (6 by 24 hour infusion) courses have been given. Re-treatment has been given following relapse.</p><p>&nbsp;</p><p>During or immediately after administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urothelial toxicity. See Section 4.4.</p><p>&nbsp;</p><p>For prophylaxis of haemorrhagic cystitis, Holoxan &nbsp;should be used in combination with mesna.</p><p>&nbsp;</p><p><u>Use in Patients with Renal Impairment</u></p><p>&nbsp;</p><p>In patients with renal impairment, particularly in those with severe renal impairment, decreased renal excretion may result in increased plasma levels of Holoxan &nbsp;and its metabolites. This may result in increased toxicity (e.g., neurotoxicity, nephrotoxicity, haematotoxicity) and should be considered when determining the dosage in such patients. See section 4.3.</p><p>Holoxan &nbsp;and its metabolites are dialyzable. <u>Use in Patients with Hepatic Impairment</u></p><p>&nbsp;</p><p>Hepatic impairment, particularly if severe, may be associated with decreased activation of Holoxan . This may alter the effectiveness of Holoxan &nbsp;treatment. Low serum albumin and hepatic impairment are also considered risk factors for the development of CNS toxicity. Hepatic impairment may increase the formation of a metabolite that is believed to cause or contribute to CNS toxicity and also contribute to nephrotoxicity. This should be considered when selecting the dose and interpreting response to the dose selected. See section</p><p>4.3.</p><p>&nbsp;</p><p><u>Use in Paediatric Patients</u></p><p>&nbsp;</p><p>In children, the dosage and administration should be determined by the tumour type, tumour stage, the general condition of the patient, any previous cytotoxic therapy, and whether chemotherapy or radiotherapy is to be administered concurrently. Clinical trials have involved doses of:</p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 g/m&sup2; over 24 hours</p><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9 g/m&sup2; equally fractionated as single daily doses over 5 days</p><p>&nbsp;</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9 g/m&sup2; as a continuous infusion over 72 hours repeated at three weekly intervals<strong>.</strong></p><p>&nbsp;</p><p><u>Use in Elderly Patients</u></p><p>&nbsp;</p><p>In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See Section 5.2).</p><p>&nbsp;</p><p>Administration:</p><p>&nbsp;</p><p>Holoxan &nbsp;is inert until activated by enzymes in the liver. However, safe handling is required and advice is included under Pharmaceutical Precautions. The dry contents of a vial should be dissolved in Water for Injections as follows:</p><p>&nbsp;</p><p>1 g vial: add 12.5 ml of Water for Injections</p><p>&nbsp;</p><p>The resultant solution of 8% of Holoxan &nbsp;should not be injected directly into the vein. &nbsp;The solution may be:</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diluted to less than a 4% solution and injected directly into the vein, with the patient supine.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infused in 5% dextrose-saline or normal saline over 30-120 mins.</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injected directly into a fast-running infusion,</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; made up in 3 x 1 litres of dextrose-saline or normal saline and infused over 24 hours. Each litre should be given over eight hours, and should be freshly made up immediately before infusion.</p><p>&nbsp;</p><p>Care should be taken that extravasation does not take place, however, should it occur local tissue damage is unlikely and no specific measures need be taken. Repeated intravenous injections of large doses of Holoxan &nbsp;have resulted in local irritation.</p><p>&nbsp;</p><p>Mesna&nbsp; should be used to prevent urothelial toxicity.</p><p>&nbsp;</p><p>Where Holoxan &nbsp;is used as an i.v. bolus, increased dosages of mesna are recommended in children, patients whose urothelium may be damaged from previous therapies and those who are not adequately protected by the standard dose of mesna.</p><p>&nbsp;</p><p>The patient should be well hydrated and maintained in fluid balance, replacement fluids being given as necessary to achieve this. The fluid intake of patients on the intermittent regimen should be at least 2 litres in 24 hours. As Holoxan &nbsp;may exert an antidiuretic effect, a diuretic may be necessary to ensure an adequate urinary output.</p><p>&nbsp;</p><p>Urine should be sent for laboratory analysis before, and at the end of, each course of treatment, and the patient should be monitored for output and evidence of proteinuria and haematuria at regular intervals (4-hourly if possible) throughout the treatment period. The patient should be instructed to report any signs or symptoms of cystitis. &nbsp;Holoxan &nbsp;should be avoided in patients with cystitis from any cause until it has been treated.</p><p>&nbsp;</p><p>Antiemetics given before, during and after therapy may reduce nausea and vomiting. &nbsp;Oral hygiene is important.</p><p>&nbsp;</p><p>If leucocyte count is below 4,000/mm&sup3; or the platelet count is below</p><p>100,000/mm&sup3;, treatment with Holoxan &nbsp;should be withheld until the blood count returns to normal.</p><p>&nbsp;</p><p>There should be no signs or symptoms of urothelial toxicity or renal or hepatic impairment prior to the start of each course of Holoxan .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Holoxan  is contra-indicated in patients with:

•	known hypersensitivity to Holoxan . See section 4.4
•	urinary outflow obstruction
•	severely impaired bone-marrow function (especially in patients previously treated with cytotoxic agents or radiotherapy)
•	inflammation of the urinary bladder (cystitis)
•	impaired renal function - serum creatinine greater than 120 mcmol/l or 1.5 mg/100 ml
•	hepatic impairment - bilirubin greater than 17 mcmol/l or 1 mg/100 ml, or serum transaminases or alkaline phosphatase more than 2.5 times the upper limit of normal
•	acute infections

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In individual patients, risk factors for Holoxan &nbsp;toxicities and their sequelae described here and in other sections may constitute contraindications. In such situations, individual assessment of risk and expected benefits is necessary. Adverse reactions, depending on their severity, may require dosage modification or discontinuation of treatment</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>WARNINGS</p><p>&nbsp;</p><p><u>Myelosuppression, Immunosuppression, Infections</u></p><p>&nbsp;</p><p>Treatment with Holoxan &nbsp;may cause myelosuppression and significant suppression of immune responses, which can lead to severe infections. Fatal outcome of Holoxan -associated myelosuppression has been reported.</p><p>&nbsp;</p><p>Administration of Holoxan &nbsp;is normally followed by a reduction in the leukocyte count. The nadir of the leukocyte count tends to be reached</p><p>&nbsp;</p><p>approximately during the second week after administration. Subsequently, the leukocyte count rises again.</p><p>&nbsp;</p><p>Severe myelosuppression and immunosuppression must be expected particularly in patients pre-treated with and/or receiving concomitant chemotherapy/haematotoxic agents, immunosuppressants and/or radiation therapy( See Section 4.5).</p><p>&nbsp;</p><p>Where indicated, use of haematopoiesis-stimulating agents (colonystimulating factors and erythropoiesis-stimulating agents) may be considered to reduce the risk of myelosuppressive complications and/or help facilitate the delivery of the intended dosing. For information on a potential interaction with G-CSF and</p><p>GM-CSF (granulocyte colonystimulating factor, granulocyte macrophage colony-stimulating factor) (See section 4.5).</p><p>&nbsp;</p><p>The risk of myelosuppression is dosedependent and is increased with administration of a single high dose compared to fractionated administration.</p><p>&nbsp;</p><p>The risk of myelosuppression is increased in patients with reduced renal function.</p><p>&nbsp;</p><p>Severe immunosuppression has led to serious, sometimes fatal, infections. Infections reported with Holoxan &nbsp;include pneumonias, as well as other bacterial, fungal, viral, and parasitic infections. Sepsis and septic shock also have been reported.</p><p>&nbsp;</p><p>Latent infections can be reactivated. In patients treated with Holoxan , reactivation has been reported for various viral infections.</p><p>&nbsp;</p><p>Close haematologic monitoring is recommended. White blood cell count, platelet count, and haemoglobin levels should be obtained prior to each administration and at appropriate intervals after administration.</p><p>&nbsp;</p><p><u>Central </u><u>Nervous System Toxicity, Neurotoxicity</u></p><p>&nbsp;</p><p>Administration of Holoxan &nbsp;can cause CNS toxicity and other neurotoxic effects (see Section 4.8).</p><p>&nbsp;</p><p>Holoxan &nbsp;neurotoxicity may become manifest within a few hours to a few days after first administration and in most cases resolves within 48 to 72 hours of Holoxan &nbsp;discontinuation. Symptoms may persist for longer periods of time. Occasionally, recovery has been incomplete. Fatal outcome of CNS toxicity has been reported.</p><p>&nbsp;</p><p>Recurrence of CNS toxicity after several uneventful treatment courses has been reported.</p><p>&nbsp;</p><p>CNS toxicity appears to be dose dependent.</p><p>&nbsp;</p><p>Other risk factors that have been demonstrated or discussed in the literature include:</p><p>&nbsp;</p><p>&ndash; Renal dysfunction, elevated serum creatinine</p><p>&nbsp;</p><p>&ndash; Low serum albumin</p><p>&nbsp;</p><p>&ndash; Hepatic dysfunction</p><p>&nbsp;</p><p>&ndash; Low bilirubin, low haemoglobin levels, decreased white blood cell count</p><p>&nbsp;</p><p>&ndash; Acidosis, low serum bicarbonate</p><p>&nbsp;</p><p>&ndash; Electrolyte imbalances, hyponatraemia and inappropriate ADH (vasopressin)</p><p>secretion, low fluid intake</p><p>&nbsp;</p><p>&ndash; Presence of brain metastases, prior CNS disease, brain irradiation</p><p>&nbsp;</p><p>&ndash; Cerebral sclerosis, peripheral vasculopathy</p><p>&nbsp;</p><p>&ndash; Presence of tumour in lower abdomen, bulky abdominal disease</p><p>&nbsp;</p><p>&ndash; Poor performance status, advanced age</p><p>&nbsp;</p><p>&ndash; Obesity, female gender</p><p>&nbsp;</p><p>&ndash; Interactions with other medicines (e.g., aprepitant, CYP 3A4 inhibitors), alcohol, drug abuse, or pretreatment with cisplatin</p><p>&nbsp;</p><p>If encephalopathy develops, administration of Holoxan &nbsp;should be discontinued.</p><p>&nbsp;</p><p>Publications report both successful and unsuccessful use of methylene blue for the treatment and prophylaxis of Holoxan -associated encephalopathy.</p><p>&nbsp;</p><p>Due to the potential for additive effects, drugs acting on the CNS (such as antiemetics, sedatives, narcotics, or antihistamines) must be used with particular caution or, if necessary, be discontinued in case of Holoxan &nbsp;induced encephalopathy.</p><p>&nbsp;</p><p><u>Renal and Urothelial Toxicity</u></p><p>&nbsp;</p><p>Holoxan &nbsp;is both nephrotoxic and urotoxic.</p><p>&nbsp;</p><p>Glomerular and tubular kidney function must be evaluated and checked before commencement of therapy, as well as during and after treatment.</p><p>&nbsp;</p><p>Close clinical monitoring of serum and urine chemistries, including phosphorus, potassium, and other laboratory parameters appropriate for identifying nephrotoxicity and urothelial toxicity is recommended, see section</p><p>4.3.</p><p>&nbsp;</p><p><u>Nephrotoxic Effects</u></p><p>&nbsp;</p><p>Fatal outcome from nephrotoxicity has been documented.</p><p>&nbsp;</p><p>Disorders of renal function (glomerular and tubular) following Holoxan &nbsp;administration are very common. ( See 4.8).</p><p>&nbsp;</p><p>Development of a syndrome resembling SIADH (syndrome of inappropriate antidiuretic hormone secretion) has been reported with Holoxan .</p><p>&nbsp;</p><p>Tubular damage may become apparent during therapy, months or even years after cessation of treatment.</p><p>&nbsp;</p><p>Glomerular or tubular dysfunction may resolve with time, remain stable, or progress over a period of months or years, even after completion of Holoxan &nbsp;treatment.</p><p>&nbsp;</p><p>The risk of developing clinical manifestations of nephrotoxicity is increased with, for example:</p><p>&nbsp;</p><p>&ndash; large cumulative doses of Holoxan</p><p>&nbsp;</p><p>&ndash; pre-existing renal impairment</p><p>&nbsp;</p><p>&ndash; prior or concurrent treatment with potentially nephrotoxic agents</p><p>&nbsp;</p><p>&ndash; younger age in children</p><p>&nbsp;</p><p>&ndash; reduced nephron reserve as in patients with renal tumours and those having undergone renal radiation or unilateral nephrectomy.</p><p>&nbsp;</p><p><u>Urothelial </u><u>Ef</u><u>f</u><u>ects</u></p><p>&nbsp;</p><p>Holoxan &nbsp;administration is associated with urotoxic effects, which can be reduced by prophylactic use of mesna.</p><p>&nbsp;</p><p>Haemorrhagic cystitis requiring blood transfusion has been reported with Holoxan .</p><p>&nbsp;</p><p>The risk of haemorrhagic cystitis is dose-dependent and increased with administration of single high doses compared to fractionated administration.</p><p>Haemorrhagic cystitis after a single dose of Holoxan &nbsp;has been reported. Before starting treatment, it is necessary to exclude or correct any urinary tract</p><p>obstructions.</p><p>&nbsp;</p><p>During or immediately after administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity.</p><p>&nbsp;</p><p>Holoxan &nbsp;should be used with caution, if at all, in patients with active urinary tract infections.</p><p>&nbsp;</p><p>Past or concomitant radiation of the bladder or busulfan treatment may increase the risk for haemorrhagic cystitis.</p><p>&nbsp;</p><p><u>Cardiotoxicity, Use in Patients With Cardiac Disease</u></p><p>&nbsp;</p><p>Fatal outcome of Holoxan -associated cardiotoxicity has been reported.</p><p>&nbsp;</p><p>The risk of developing cardiotoxic effects is dose-dependent. It is increased in patients with prior or concomitant treatment with other cardiotoxic agents or radiation of the cardiac region and, possibly, renal impairment.</p><p>&nbsp;</p><p>Particular caution should be exercised when Holoxan &nbsp;is used in patients with risk factors for cardiotoxicity and in patients with pre-existing cardiac disease.</p><p>&nbsp;</p><p>Manifestations of cardiotoxicity reported with Holoxan &nbsp;treatment (see</p><p>Section 4.8) and include:</p><p>&nbsp;</p><p>&ndash; Supraventricular or ventricular arrhythmias, including atrial/supraventricular tachycardia, atrial fibrillation, pulseless ventricular tachycardia</p><p>&nbsp;</p><p>&ndash; Decreased QRS voltage and STsegment or T-wave changes</p><p>&nbsp;</p><p>&ndash; Toxic cardiomyopathy leading to heart failure with congestion and hypotension</p><p>&nbsp;</p><p>&ndash; Pericardial effusion, fibrinous pericarditis, and epicardial fibrosis</p><p>&nbsp;</p><p><u>Pulmonary Toxicity</u></p><p>&nbsp;</p><p>Pulmonary toxicity leading to respiratory failure as well as fatal outcome has been reported.Interstitial pneumonitis and pulmonary fibrosis have been reported with Holoxan &nbsp;treatment.</p><p>&nbsp;</p><p><u>Secondary Malignancies</u></p><p>&nbsp;</p><p>As with all cytotoxic therapy, treatment with Holoxan &nbsp;involves the risk of secondary tumours and their precursors . The secondary malignancy may develop several years after chemotherapy has been discontinued.</p><p>&nbsp;</p><p>The risk of myelodysplastic alterations, some progressing to acute leukaemias, is increased.</p><p>&nbsp;</p><p><u>Veno-occlusive Liver Disease</u></p><p>&nbsp;</p><p>Veno-occlusive liver disease has been reported with chemotherapy that included Holoxan &nbsp;and also is a known complication with another oxazaphosphorine cytotoxic agent.</p><p><u>Genotoxicity</u></p><p>See section 4.6.</p><p><u>Effects on Fertility</u></p><p>&nbsp;</p><p>See section 4.6.</p><p>&nbsp;</p><p><u>Female Patients</u></p><p>&nbsp;</p><p>Amenorrhea has been reported in patients treated with Holoxan . In addition, with another oxazaphosphorine cytotoxic agent, oligomenorrhea has been reported, see section 4.6.</p><p>&nbsp;</p><p><u>Male Patients</u></p><p>&nbsp;</p><p>Men treated with Holoxan &nbsp;may develop oligospermia or azoospermia, see section 4.6.</p><p>&nbsp;</p><p><u>Anaphylactic/Anaphylactoid Reactions, Cross-sensitivity</u></p><p>&nbsp;</p><p>Anaphylactic/anaphylactoid reactions have been reported in association with Holoxan .</p><p>&nbsp;</p><p>Cross-sensitivity between oxazaphosphorine cytotoxic agents has been reported.</p><p>&nbsp;</p><p><u>Impairment of Wound Healing</u></p><p>&nbsp;</p><p>Holoxan &nbsp;may interfere with normal wound healing. <u>Paravenous Administration</u></p><p>The cytotoxic effect of Holoxan &nbsp;occurs after its activation, which takes place mainly in the liver. Therefore, the risk of tissue injury from accidental paravenous administration is low.</p><p>&nbsp;</p><p>In case of accidental paravenous administration of Holoxan , the infusion should be stopped immediately, the extravascular Holoxan &nbsp;solution should be aspirated with the cannula in place, and other measures should be instituted as appropriate.</p><p>&nbsp;</p><p><u>Use in Patients With Renal Impairment</u></p><p>&nbsp;</p><p>In patients with renal impairment, particularly in those with severe renal impairment, decreased renal excretion may result in increased plasma levels of Holoxan &nbsp;and its metabolites. This may result in increased toxicity (e.g., neurotoxicity, nephrotoxicity, haematotoxicity) and should be considered when determining the dosage in such patients.</p><p>&nbsp;</p><p><u>Use in Patients With Hepatic Impairment</u></p><p>&nbsp;</p><p>Hepatic impairment, particularly if severe, may be associated with decreased activation of Holoxan . This may alter the effectiveness of Holoxan &nbsp;treatment. Low serum albumin and hepatic impairment are also considered risk factors for the development of CNS toxicity. Hepatic impairment may increase the formation of a metabolite that is believed to cause or contribute to CNS toxicity and also contribute to nephrotoxicity.</p><p>&nbsp;</p><p>This should be considered when selecting the dose and interpreting response to the dose selected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Planned co administration or sequential administration of other substances or treatments that could increase the likelihood or severity of toxic effects (by means of pharmacodynamic or pharmacokinetic interactions) requires careful individual assessment of the expected benefit and the risks. Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention.</p><p>&nbsp;</p><p>Patients being treated with Holoxan &nbsp;and agents that reduce its activation should be monitored for a potential reduction of therapeutic effectiveness and the need for dose adjustment.</p><p>&nbsp;</p><p>Increased haematotoxicity and/or immunosuppression may result from a combined effect of Holoxan &nbsp;and, for example:</p><p>&nbsp;</p><p>&ndash; ACE inhibitors: ACE inhibitors can cause leukopenia.</p><p>&nbsp;</p><p>&ndash; Carboplatin</p><p>&nbsp;</p><p>&ndash; Cisplatin</p><p>&nbsp;</p><p>&ndash; Natalizumab</p><p>&nbsp;</p><p>Increased cardiotoxicity may result from a combined effect of Holoxan &nbsp;and, for example:</p><p>&nbsp;</p><p>&ndash; Anthracyclines</p><p>&nbsp;</p><p>&ndash; Irradiation of the cardiac region</p><p>&nbsp;</p><p>Increased pulmonary toxicity may result from a combined effect of Holoxan &nbsp;and, for example:</p><p>&nbsp;</p><p>&ndash; Amiodarone</p><p>&nbsp;</p><p>&ndash; G-CSF, GM-CSF (granulocyte colonystimulating factor, granulocyte macrophage colony-stimulating factor)</p><p>&nbsp;</p><p>Increased nephrotoxicity may result from a combined effect of Holoxan &nbsp;and, for example:</p><p>&nbsp;</p><p>&ndash; Acyclovir</p><p>&nbsp;</p><p>&ndash; Aminoglycosides</p><p>&nbsp;</p><p>&ndash; Amphotericin B</p><p>&nbsp;</p><p>&ndash; Carboplatin</p><p>&nbsp;</p><p>&ndash; Cisplatin</p><p>&nbsp;</p><p>An increased risk of developing haemorrhagic cystitis may result from a combined effect of Holoxan &nbsp;and, for example:</p><p>&nbsp;</p><p>&ndash; Busulfan</p><p>&nbsp;</p><p>&ndash; Irradiation of the bladder</p><p>&nbsp;</p><p>Additive CNS effects may result from a combined effect of Holoxan &nbsp;and, for example:</p><p>&nbsp;</p><p>&ndash; Antiemetics</p><p>&nbsp;</p><p>&ndash; Antihistamines</p><p>&nbsp;</p><p>&ndash; Narcotics</p><p>&nbsp;</p><p>&ndash; Sedatives</p><p>&nbsp;</p><p>Inducers of human hepatic and extrahepatic microsomal enzymes</p><p>(e.g.,cytochrome P450 enzymes):</p><p>&nbsp;</p><p>The potential for increased formation of metabolites responsible for cytotoxicity and other toxicities (depending on the enzymes induced) must be considered in case of prior or concomitant treatment with, for example:</p><p>&nbsp;</p><p>&ndash; Carbamazepine</p><p>&nbsp;</p><p>&ndash; Corticosteroids</p><p>&nbsp;</p><p>&ndash; Rifampin</p><p>&nbsp;</p><p>&ndash; Phenobarbital</p><p>&nbsp;</p><p>&ndash; Phenytoin</p><p>&nbsp;</p><p>&ndash; St. John&rsquo;s Wort</p><p>&nbsp;</p><p>See also aprepitant below.</p><p>&nbsp;</p><p>Inhibitors of CYP 3A4: Reduced activation and metabolism of Holoxan &nbsp;may alter the effectiveness of Holoxan &nbsp;treatment. Inhibition of CYP 3A4 can also lead to increased formation of an Holoxan &nbsp;metabolite associated with CNS and nephrotoxicity. CYP 3A4 inhibitors include:</p><p>&nbsp;</p><p>&ndash; Ketoconazole</p><p>&nbsp;</p><p>&ndash; Fluconazole</p><p>&nbsp;</p><p>&ndash; Itraconazole</p><p>&nbsp;</p><p>&ndash; Sorafenib</p><p>&nbsp;</p><p>See also aprepitant below.</p><p>&nbsp;</p><p>Aprepitant: Reports suggest increased Holoxan &nbsp;neurotoxicity in patients receiving antiemetic prophylaxis with aprepitant, which is both an inducer and a moderate inhibitor of CYP 3A4.</p><p>&nbsp;</p><p>Docetaxel: Increased gastrointestinal toxicity has been reported when Holoxan &nbsp;was administered before docetaxel infusion.</p><p>&nbsp;</p><p>Coumarin derivatives: Increased INR (increased international normalized ratio)</p><p>has been reported in patients receiving Holoxan &nbsp;and warfarin.</p><p>&nbsp;</p><p>Vaccines: The immunosuppressive effects of Holoxan &nbsp;can be expected to reduce the response to vaccination. Use of live vaccines may lead to vaccine induced infection.</p><p>&nbsp;</p><p>Tamoxifen: Concomitant use of tamoxifen and chemotherapy may increase the risk of thromboembolic complications.</p><p>&nbsp;</p><p>Cisplatin: Cisplatin-induced hearing loss can be exacerbated by concurrent Holoxan &nbsp;therapy (see also interactions above).</p><p>&nbsp;</p><p>Irinotecan: Formation of the active metabolite of irinotecan may be reduced when irinotecan is administered with Holoxan .</p><p>&nbsp;</p><p>Alcohol: In some patients, alcohol may increase Holoxan -induced nausea and vomiting.</p><p>&nbsp;</p><p>Concurrent administration of antidiabetic agents, such as sulfonylureas and Holoxan &nbsp;may enhance the hypoglycaemic effects of the former drugs.</p><p>&nbsp;</p><p>Theoretical interactions of Holoxan &nbsp;and allopurinol resulting in an increased severity of bone marrow depression.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>&nbsp;</p><p>The administration of Holoxan &nbsp;during organogenesis has been shown to have a fetotoxic effect in mice, rats, and rabbits and therefore may cause fetal damage when administered to pregnant women.</p><p>&nbsp;</p><p>There are only very limited data available on the use of Holoxan &nbsp;during pregnancy in humans. Fetal growth retardation and neonatal anaemia have been reported following exposure to Holoxan -containing chemotherapy regimens during pregnancy. Multiple congenital deviations have been reported after use during the first trimester of pregnancy. Animal data generated with cyclophosphamide, another oxazaphosphorine cytotoxic agent suggest that an</p><p>&nbsp;</p><p>increased risk of failed pregnancy and malformations may persist after discontinuation of the agent as long as oocytes/follicles exist that were exposed to the agent during any of their maturation phases.</p><p>&nbsp;</p><p>In addition, exposure to cyclophosphamide has been reported to cause miscarriage, malformations (following exposure during the first trimester), and neonatal effects, including leukopenia, pancytopenia, severe bone marrow hypoplasia, and gastroenteritis.</p><p>&nbsp;</p><p>Based on the results of animal studies, human case reports and the substance&#39;s mechanism of action, the use of Holoxan &nbsp;during pregnancy, particularly in the first trimester, is advised against.</p><p>&nbsp;</p><p>In every individual case, the benefits of the treatment will have to be weighed against possible risks for the fetus.</p><p>&nbsp;</p><p>If Holoxan &nbsp;is used during pregnancy, or if the patient becomes pregnant while taking this drug or after treatment, the patient should be apprised of the potential hazard to a fetus.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>&nbsp;</p><p>Holoxan &nbsp;is passed into the breast milk and may cause neutropenia, thrombocytopenia, low haemoglobin concentrations and diarrhea in children. Holoxan &nbsp;is contra-indicated for breast-feeding (see section 4.3).</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>&nbsp;</p><p>Holoxan &nbsp;interferes with oogenesis and spermatogenesis. It may cause sterility in both sexes.</p><p>&nbsp;</p><p>Development of sterility appears to depend on the dose of Holoxan , duration of therapy, and state of gonadal function at the time of treatment.</p><p>&nbsp;</p><p>Holoxan &nbsp;may cause transient or permanent amenorrhea in women and oligospermia or azoospermia in men.</p><p>&nbsp;</p><p><u>Female Patients</u></p><p>&nbsp;</p><p>Women treated with Holoxan &nbsp;should be informed prior to treatment about the possibility to save and preserve their eggs.</p><p>&nbsp;</p><p>The risk of permanent chemotherapy-induced amenorrhea is increased in older women.</p><p>&nbsp;</p><p>Girls treated with Holoxan &nbsp;during prepubescence may develop secondary sexual characteristics normally and have regular menses.</p><p>&nbsp;</p><p>Girls treated with Holoxan &nbsp;during prepubescence subsequently have conceived.</p><p>&nbsp;</p><p>Girls who have retained ovarian function after completing treatment are at increased risk of developing premature menopause.</p><p>&nbsp;</p><p><u>Male Patients</u></p><p>&nbsp;</p><p>Men treated with Holoxan &nbsp;should be informed prior to treatment about the possibility to save pre-produced sperm kept in proper conditions.</p><p>&nbsp;</p><p>Sexual function and libido generally are unimpaired in these patients.</p><p>&nbsp;</p><p>Boys treated with Holoxan &nbsp;during prepubescence may develop secondary sexual characteristics normally, but may have oligospermia or azoospermia.</p><p>&nbsp;</p><p>Some degree of testicular atrophy may occur.</p><p>&nbsp;</p><p>Azoospermia may be reversible in some patients, though the reversibility may not occur for several years after cessation of therapy.</p><p>&nbsp;</p><p>Men treated with Holoxan &nbsp;have subsequently fathered children.</p><p>&nbsp;</p><p><strong>Genotoxicity</strong></p><p>&nbsp;</p><p>Holoxan &nbsp;is genotoxic and mutagenic in male and female germ cells. Therefore, women should not become pregnant and men should not father a child during therapy with Holoxan .</p><p>&nbsp;</p><p>Women treated with Holoxan &nbsp;should take contraceptive measures for at least</p><p>1 year after discontinuation of Holoxan &nbsp;therapy.</p><p>Men should not father a child for up to 6 months after the end of therapy. Sexually active women and men should use effective methods of contraception</p><p>during these periods of time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potential side-effects on the central nervous system may transiently impair the ability to operate machinery and motor vehicles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions and frequencies below are based on publications describing clinical experience with fractionated administration of Holoxan &nbsp;as monotherapy with a total dose of 4 to 12 g/m2 per course.</p><p>&nbsp;</p><p>ADR frequency is based upon the following scale: Very common (&ge;1/10); Common (&ge;1/100 - &lt;1/10), Uncommon (&ge;1/1,000 - &lt;1/100), Rare (&ge;1/10,000 -&nbsp;&lt;1/1,000), Very rare (&lt;1/10,000), Not known (adverse reactions reported in the post-marketing experience).</p><table border="1" align="left" cellspacing="1" cellpadding="1"><thead><tr><th scope="col"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class (SOC)</strong></p></td></tr></tbody></table></th><th scope="col"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Adverse Reaction</strong></p></td></tr></tbody></table></th><th scope="col"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Frequency Category</strong></p></td></tr></tbody></table></th></tr></thead><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>INFECTIONS AND INFESTATIONS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Infections (including reactivation of latent infections)</p><p>Sepsis (septic shock)*</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Common</p><p>&nbsp;</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYCTS AND POLYPS)</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Secondary tumors*</p><p>(including Urinary tract carcinoma, Myelodysplastic syndrome, Acute leukaemia, Acute lymphocytic leukaemia, Lymphoma [Non-Hodgkin&rsquo;s lymphoma], Sarcomas, Renal cell carcinoma, Thyroid cancer)</p><p>Progressions of underlying malignancies*</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>BLOOD AND LYMPHATIC SYSTEM DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Myelosuppression</p><p>&nbsp; - Leukopenia</p><p>&nbsp; - Thrombocytopenia*</p><p>&nbsp; - Anaemia</p><p>&nbsp; - Agranulocytosis</p><p>Haematotoxicity*</p><p>&nbsp; - Haemolytic anaemia</p><p>&nbsp; - Methaemoglobinaemia</p><p>Febrile bone marrow aplasia</p><p>Disseminated intravascular coagulation</p><p>Haemolytic uremic syndrome</p><p>Neonatal anaemia</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Very common</p><p>Very common</p><p>Very common</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>IMMUNE SYSTEM DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Angioedema*</p><p>Anaphylactic reaction</p><p>Immunosuppression</p><p>Urticaria</p><p>Hypersensitivity reaction</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>ENDOCRINE DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>METABOLISM AND NUTRITION DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Decreased Appetite</p><p>Tumor lysis syndrome</p><p>Metabolic acidosis</p><p>Hypokalaemia</p><p>Hypocalcaemia</p><p>Hypophosphataemia</p><p>Hyperglycaemia</p><p>Polydipsia</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Common</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>PSYCHIATRIC DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Mutism</p><p>Mental status change (includine mania, paranoia, delusion, delirium, catatonia, amnesia, panic attack)</p><p>Echolalia</p><p>Perseveration</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>Not known</p><p>&nbsp;</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>NERVOUS SYSTEM DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Central nervous system toxicity</p><p>&nbsp; - Encephalopathy</p><p>&nbsp; - Faecal incontinence</p><p>&nbsp;- Status epilepticus* (convulsive and nonconvulsive)</p><p>&nbsp; - Movement disorder</p><p>&nbsp; - Extrapyramidal disorder</p><p>&nbsp; - Gait disturbance</p><p>&nbsp; - Dysarthria</p><p>Peripheral neuropathy</p><p>&nbsp; - Hypoesthesia</p><p>&nbsp;- Paresthesia</p><p>Asterixis</p><p>Neuralgia</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>EYE DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Visual impairment</p><p>Conjunctivitis</p><p>Eye irritation</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>EA</strong><strong>R AND LABYRINTH DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Deafness</p><p>Vertigo</p><p>Tinnitus</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>CARDIAC DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Cardiotoxicity*</p><p>Arrythmia (including supraventricular and ventricular arrhythmia)</p><p>Atrial fibrillation</p><p>Premature atrial contractions</p><p>Bradycardia</p><p>Cardiac arrest*</p><p>Myocardial infarction</p><p>Cardiac failure*</p><p>Myocardial haemorrhage</p><p>Angina pectoris</p><p>Cardiomyopathy* (including congestive cardiomyopathy )</p><p>Electrocardiogram ST-segment abnormal</p><p>Electrocardiogram T- wave inversion</p><p>Electrocardiogram QRS complex abnormal</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Uncommon</p><p>Not known</p><p>&nbsp;</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>&nbsp;</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>VASCULAR </strong><strong>DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Hypotension</p><p>Pulmonary embolism</p><p>Deep vein thrombosis</p><p>Capillary leak syndrome</p><p>Vasculitis</p><p>Hypertension</p><p>Flushing</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Uncommon</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Respiratory failure*</p><p>Acute respiratory distress syndrome*</p><p>Pulmonary hypertension</p><p>Interstitial lung disease* (as manifested by Pulmonary fibrosis)</p><p>Pneumonitis*</p><p>Pulmonary oedema*</p><p>Pleural effusion</p><p>Dyspnea</p><p>Hypoxia</p><p>Cough</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>&nbsp;</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>GASTROINTESTINAL DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Nausea/Vomiting</p><p>Diarrhoea</p><p>Stomatitis</p><p>Enterocolitis</p><p>Pancreatitis</p><p>Ileus</p><p>Gastrointestinal haemorrhage</p><p>Mucosal ulceration</p><p>Constipation</p><p>Abdominal pain</p><p>Salivary hypersecretion</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Very common</p><p>Uncommon</p><p>Uncommon</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>HEPATOBILIARY DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Hepatotoxicity</p><p>&nbsp; - Hepatic failure</p><p>Veno-occlusive liver disease</p><p>Portal vein thrombosis</p><p>Cytolytic hepatitis</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Common</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Alopecia</p><p>Dermatitis</p><p>Papular rash</p><p>Toxic epidermal necrolysis</p><p>Stevens-Johnson syndrome</p><p>Palmar-plantar erythrodysesthesia syndrome</p><p>Radiation recall dermatitis</p><p>Skin necrosis</p><p>Facial swelling</p><p>Rash</p><p>Pruritus</p><p>Erythema</p><p>Skin hyperpigmentation</p><p>Hyperhidrosis</p><p>Nail disorder</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Very common</p><p>Rare</p><p>Rare</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Rhabdomyolysis</p><p>Osteomalacia</p><p>Rickets</p><p>Growth retardation</p><p>Myalgia</p><p>Arthralgia</p><p>Muscle twitching</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>RENAL AND URINARY DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Haemorrhagic cystitis</p><p>Haematuria</p><p>Renal dysfunction*</p><p>&nbsp; - Acute renal failure</p><p>&nbsp; - Chronic renal failure</p><p>&nbsp; - Aminoaciduria</p><p>&nbsp; - Phosphaturia</p><p>&nbsp; - Fanconi syndrome</p><p>&nbsp;- Tubulointerstitial nephritis</p><p>Renal structural damage</p><p>Nephrogenic diabetes insipidus</p><p>Polyuria</p><p>Enuresis</p><p>Feeling of residual urine</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Very common</p><p>Very common</p><p>Very common</p><p>Very common</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>REPRODUCTIVE SYSTEM AND BREAST DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Infertility</p><p>Ovarian failure</p><p>Premature menopause</p><p>Amenorrhea</p><p>Ovulation disorder</p><p>Azoospermia</p><p>Oligospermia</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>CONGENITAL, FAMILIAL AND GENETIC DISORDERS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Fetal growth retardation</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Not known</p></td></tr></tbody></table></td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS</strong></p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Phlebitis</p><p>Fatigue</p><p>Malaise</p><p>Multiorgan failure*</p><p>General physical deterioration Injection/Infusion site reactions</p><p>Oedema</p><p>Pain</p><p>Pyrexia</p><p>Chills</p></td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Common</p><p>Uncommon</p><p>Not known</p><p>Not known</p><p>Not known</p><p>&nbsp;</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>*&nbsp; including fatal outcomes</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of Holoxan is important. It allows continued monitoring of the benefit/risk balance of Holoxan. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system as per following contact details:</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Serious consequences of overdosage include manifestations of dose-dependent toxicities such as CNS toxicity, nephrotoxicity, myelosuppression, and mucositis. See Section 4.4.</p><p>&nbsp;</p><p>Patients who received an overdose should be closely monitored for the development of toxicities.</p><p>&nbsp;</p><p>No specific antidote for Holoxan &nbsp;is known.</p><p>&nbsp;</p><p>Overdosage should be managed with supportive measures, including appropriate, state-of-the-art treatment for any concurrent infection, myelosuppression, or other toxicity, should it occur.</p><p>&nbsp;</p><p>Holoxan &nbsp;as well as Holoxan &nbsp;metabolites are dialyzable. Consider haemodialysis in cases of severe overdose presenting early, particularly in patients with renal impairment.</p><p>&nbsp;</p><p>Cystitis prophylaxis with mesna may be helpful in preventing or limiting urotoxic effects with overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Holoxan &nbsp;is an antineoplastic, a cytotoxic alkylating agent. It is a prodrug and shows no in vitro cytotoxic activity until activated by microsomal enzymes.</p><p>The cytotoxic activity of Holoxan &nbsp;(alkylation of the nucleophilic centres in the cells) is associated with the activated oxazaphosphorine ring hydroxylated at the C4 atom which interacts with DNA-DNA cross linking. &nbsp;This activity manifests itself by blocking the late S and early G2 phases of the cell cycle.</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>Ewing&rsquo;s sarcoma</p><p>&nbsp;</p><p>In a randomized controlled trial, 518 patients (87% under 17 years of age) with Ewing&rsquo;s Sarcoma, primitive neuroectodermal tumour of bone or primitive sarcoma of bone were randomized to Holoxan /etoposide alternating with standard treatment, or to standard treatment alone. In those with no metastases at baseline, there was a statistically significant improvement in 5 year survival for those receiving Holoxan &nbsp;/etoposide (69%) compared to those on standard treatment alone (54%). Overall survival at 5 years was 72% in the Holoxan /etoposide group compared to 61% in the standard treatment group. Similar toxicities were observed in both treatment arms. In those with</p><p>metastases at baseline, there was no difference in 5 year event-free survival or 5 year overall survival between treatment groups.</p><p>&nbsp;</p><p>In a randomized comparative study of Holoxan &nbsp;(VAIA regimen) and cyclophosphamide (VACA regimen) in 155 patients with standard risk Ewing&rsquo;s</p><p>&nbsp;</p><p>sarcoma (83% under 19 years of age), no difference in event free survival or overall survival was demonstrated. Less toxicity was demonstrated for the Holoxan &nbsp;regimen.</p><p>&nbsp;</p><p>Other paediatric cancers</p><p>&nbsp;</p><p>Holoxan &nbsp;has been widely investigated in uncontrolled prospective exploratory studies in children. Various dosage schedules and regimens, in combination with other antitumour agents, have been used. The following paediatric cancers have been investigated: rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcoma, germ cell tumours, osteosarcoma, non-Hodgkins lymphoma, Hodgkins Lymphoma , acute lymphoblastic leukaemia, neuroblastoma, Wilms tumour, and malignant CNS tumours.</p><p>&nbsp;</p><p>Favourable partial responses, complete responses and survival rates have been documented.</p><p>&nbsp;</p><p>A variety of dosage schedules and regimens of Holoxan &nbsp;in combination with other antitumor agents, are used. The prescriber should refer to chemotherapy regimens for specific tumour type &nbsp;in choosing a specific dosage, mode of administration and schedules.</p><p>&nbsp;</p><p>Usually the doses of Holoxan &nbsp;in pediatric tumors range from 0.8 to 3 g/m2/day for 2-5 days for a total dose of 4-12 g/m2 for chemotherapy course.</p><p>&nbsp;</p><p>Fractionated administration of Holoxan &nbsp;is performed as intravenous infusion over a period ranging between 30 minutes and 2 hours, depending on the infusion volume or recommendations of protocol:</p><p>&nbsp;</p><p>Uroprotection with mesna is mandatory during Holoxan &nbsp;administration with a dose equivalent to 80-120 % of Holoxan . It is recommended to prolong</p><p>Mesna infusion to 12-48 hours after the end of Holoxan &nbsp;infusion. 20 % of the whole Mesna dose should be given as i.v start bolus. Hyperhydration with at least 3000 ml/m2 is required during Holoxan &nbsp;infusion and for 24-48 hours after the end of Holoxan &nbsp;administration.</p><p>&nbsp;</p><p>Under treatment with Holoxan , especially in case of long-term treatment, sufficient diuresis and regular control of renal function will be required. Children 5 years of age or younger may be more susceptible to Holoxan - induced renal toxicity than older children or adults. Severe nephrotoxicity leading to Fanconi&rsquo;s syndrome has been reported. Progressive tubular damage resulting in potentially debilitating hypophosphataemia and rickets has been reported rarely but should be taken into consideration.</p><p>&nbsp;</p><p>Paediatric data from randomized controlled clinical studies are limited.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Holoxan &nbsp;is rapidly absorbed from the site of administration, activation of Holoxan &nbsp;is primarily in the liver by microsomal mixed function oxidases. Elimination of metabolised Holoxan &nbsp;is primarily via the kidneys. &nbsp;The serum half-life ranges between 4 - 8 hours depending on the dose and dosage regimen. Over 80% of a single dose of Holoxan &nbsp;was excreted in the urine within 24 hours. Approximately 80% of the dose was excreted as parent compound. Significant quantities of unchanged Holoxan &nbsp;were found in the cerebrospinal fluid consistent with the high lipid solubility of the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzyl alcohol-containing solutions can reduce the stability of Holoxan .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
 
The reconstituted solution should be used immediately.  The product does not contain a preservative, therefore microbial stability cannot be guaranteed. When prepared under strict aseptic conditions, Holoxan  is, as a 4% solution, however, chemically stable for 7 days at room temperature with Water for Injections, 0.9% saline, dextrose/saline and dextrose solutions. Holoxan  and mesna when prepared under strict aseptic conditions at the recommended dilutions are chemically stable with:

(i) 0.9% saline and dextrose/saline solution for one week at room temp. (ii) Water for Injections for one week under refrigeration.
(iii) 5% dextrose solution for 24 hours at room temperature, and

(iv) 0.9% saline solution for 28 days at room temperature.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.</p><p>&nbsp;</p><p>Keep container in outer carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I or Type III clear glass injection vial with bromobutyl rubber closure and beading cap. Vials are packed singly in a cardboard box.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.</p><p>Before parenteral administration, the substance must be completely dissolved. The following protective recommendations are advised during handling due to</p><p>the toxic nature of the substance:</p><p>&nbsp;</p><p>Reconstitution and administration must be undertaken only by trained personnel. Pregnant staff and breastfeeding mothers should be excluded.</p><p>&nbsp;</p><p>Protective clothing, goggles, masks and disposable PVC or latex gloves should be worn.</p><p>&nbsp;</p><p>A designated area should be defined for reconstitution (preferably under a laminar-airflow system). &nbsp;The work surface should be protected by a</p><p>disposable, plastic backed absorbent paper. Accidental contact with the skin or eyes should be treated immediately by copious lavage with water. Soap and water should then be used on non-mucous membranes. Spillage should be removed by dry or moist disposable towels.</p><p>&nbsp;</p><p>Care must be taken in the disposal of all waste material (syringes, needles and disposable towels etc.) Used items should be placed in appropriate secure</p><p>&nbsp;</p><p>containers in readiness for destruction in an appropriate high-temperature incinerator with an after-burner.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Baxter Oncology GmbH
Kantstraße 2
33790 Halle/Westphalia
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>